HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 79 MUSD, of which 26 MUSD were sales in the USA.
The royalty for the third quarter amounted to 57 MSEK (6.1 MEUR). Medivir’s royalties based on sales for the third quarter are calculated from the third royalty tier.
Help employers find you! Check out all the jobs and post your resume.
